Investment analysts at StockNews.com began coverage on shares of Can-Fite BioPharma (NYSE:CANF – Get Free Report) in a note issued to investors on Monday. The brokerage set a “hold” rating on the stock.
Other equities analysts have also recently issued reports about the stock. Alliance Global Partners boosted their target price on shares of Can-Fite BioPharma from $8.25 to $12.00 in a research report on Monday, July 24th. HC Wainwright cut their target price on Can-Fite BioPharma from $34.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, October 24th.
Can-Fite BioPharma Stock Up 0.5 %
Can-Fite BioPharma (NYSE:CANF – Get Free Report) last announced its earnings results on Thursday, August 31st. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.14. The firm had revenue of $0.20 million for the quarter, compared to analyst estimates of $0.20 million. Can-Fite BioPharma had a negative net margin of 1,231.78% and a negative return on equity of 143.29%. On average, research analysts expect that Can-Fite BioPharma will post -1.92 EPS for the current year.
Institutional Investors Weigh In On Can-Fite BioPharma
A hedge fund recently bought a new stake in Can-Fite BioPharma stock. Virtu Financial LLC acquired a new stake in shares of Can-Fite BioPharma Ltd. (NYSE:CANF – Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 56,322 shares of the company’s stock, valued at approximately $52,000. Virtu Financial LLC owned approximately 0.21% of Can-Fite BioPharma as of its most recent SEC filing. 1.54% of the stock is currently owned by institutional investors.
Can-Fite BioPharma Company Profile
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.
- Five stocks we like better than Can-Fite BioPharma
- Russell 2000 Index, How Investors Use it For Profitable Trading
- MarketBeat Week in Review – 10/30 – 11/3
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Shocking uranium play that hedge funds kept hidden
- What are stock market earnings reports?
- Dependable dividends: Why utility stocks are on fire
Receive News & Ratings for Can-Fite BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can-Fite BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.